Techniques such as CRISPR/Cas9-mediated knockout of CXCL10 has demonstrated potential in preclinical models to ‎reduce tumor-promoting inflammation, while nanoparticle-based CXCL10 inhibitors enhance ‎immune checkpoint blockade efficacy in melanoma. This evidence concerns the gene CXCL10 and neoplasm.